Protalix BioTherapeutics, Inc.
Protalix develops recombinant enzyme replacement therapies for rare diseases using plant cell-based expression.
10-QNov 10Latest SEC filing
Nov 10Latest story
Protalix develops recombinant enzyme replacement therapies for rare diseases using plant cell-based expression.